Improving Cardiac Care in Patients with CLL Receiving BTK Inhibitors
In this slide deck, HCPs will gain deeper knowledge of appropriate assessment, monitoring, and management of cardiotoxicity-associated complications for optimal use of BTK inhibitors in CLL, particularly in patients with baseline risk factors.
Date of Last Review: October 29, 2024
Please rate your satisfaction with the content on the following statements:
Very Dissatisfied
Dissatisfied
Neutral
Satisfied
Very Satisfied
Credibility of information
Relevance of the information to my needs
Confidence to implement the learnings in my clinical practice
Please rate your satisfaction with the content on the following statements:
Credibility of information
Relevance of the information to my needs
Confidence to implement the learnings in my clinical practice